Heart Failure

This heart failure channel offers news and new technology to treat heart failure. This includes for new innovations to treat congestive heart failure (CHF). The channel includes news on HFpEF and HFrEF. Heart failure occurs when the heart is no longer able to pump as much blood as the body requires. This can lead to enlargement of the heart because the muscle works harder to supply blood, but the pumping is ineffective. This may be due to defects in the myocardium, such as an infarct, or due to structural issues such as severe valve regurgitation. The disease is divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant  or a left ventricular assist device (LVAD).

Results from study of more than 14,000 patients across the United States show the heavy impact of cardiac disease on hospitalized COVID patients. COVID-19 patients with cardiovascular diseases have in-hospital mortality rates of between 25 to 38 percent. #AHA #AHA20 #AHA2020 #COVID19 #Coronavirus #SARSCoV2

Results from study of more than 14,000 patients across the United States show the heavy impact of cardiac disease on hospitalized COVID patients. COVID-19 patients with cardiovascular diseases have in-hospital mortality rates of between 25 to 38 percent. 

News | Coronavirus (COVID-19) | November 18, 2020 | Dave Fornell, Editor
November 18, 2020 — A late-breaking study at the 2020 American Heart Association (AHA) Scientific Sessions showed...
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the  Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020

Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip was the subject of two studies, including use to aid heart transplant patients. Bottom right, the Boston Scientific Acurate neo TAVR valve performed below the Sapien 3 and CoreValve Evolut.

Feature | TCT | October 29, 2020 | Dave Fornell, Editor
Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials...
Videos | Heart Failure | October 16, 2020
The late-breaking MitraBridge Study was presented at Transcatheter Cardiovascular Therapeutics (TCT) 2020 meeting...
Effect of COVID-19 on Cardiology Highlighted in Research at ACC Quality Summit. Research examines telehealth, healthcare disparities, as well as impacts on interventional cardiology, patient-centered care.
News | Coronavirus (COVID-19) | October 14, 2020
October 14, 2020 — American College of Cardiology (ACC) Quality Summit virtual meeting Oct. 8-9, 2020, featured several...
Flexible electronics have been developed to implant in patients to constantly monitor their cardiac condition.

Flexible electronics have been developed to implant in patients to constantly monitor their cardiac condition.

Feature | October 09, 2020 | Udi Nussinovitch M.D., Ph.D.
This is an overview of some of the biggest cardiology technology advances. These innovations are covered in more detail...
Chest X-ray of a congestive heart failure patient, showing fluid in the lower portions of the lungs and an enlarged heart. Getty Images

Chest X-ray of a congestive heart failure patient, showing fluid in the lower portions of the lungs and an enlarged heart. Getty Images

News | Heart Failure | October 05, 2020
October 5, 2020 — The American College of Cardiology (ACC) says heart failure (HF) is a cardiovascular epidemic. In...
The Cardiac Dimensions Carillon Mitral Contour System, a transcatheter device used to treat functional mitral regurgitation (FMR) in patients with heart failure.
News | Heart Valve Technology | October 02, 2020
October 2, 2020 — Cardiac Dimensions announced the company has closed a $17.5 million Series C financing that will be...
The Optimizer Smart System is a pacemaker-like device that improves heart function and reduces debilitating symptoms associated with the disease, including fatigue and shortness of breath.
News | Heart Failure | September 23, 2020
September 23, 2020 – A team of cardiologists at Allegheny General Hospital (AGH), part of Allegheny Health Network (AHN...
The BRACE CORONA trial presented at ESC Congress 2020 is the First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients.
News | Coronavirus (COVID-19) | September 08, 2020
September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin-...
Navin Kapur, M.D., FAHA, FACC, FSCAI, executive director, The CardioVascular Center for Research and Innovation (CVCRI), explains the concpet of the Door-to-Unloading (DTU) Trial he is heading, one of several innovations at Tufts Medical Center in Boston. Kapur is also director, Acute Mechanical Circulatory Support Program; director, interventional research laboratories; director of Cardiac Biology Research Center, Molecular Cardiology Research Institute (MCRI), Tufts Medical Center. Photo by Dave Fornell

Navin Kapur, M.D., FAHA, FACC, FSCAI, executive director, The CardioVascular Center for Research and Innovation (CVCRI), explains the concpet of the Door-to-Unloading (DTU) Trial he is heading, one of several innovations at Tufts Medical Center in Boston. Kapur is also director, Acute Mechanical Circulatory Support Program; director, interventional research laboratories; director of Cardiac Biology Research Center, Molecular Cardiology Research Institute (MCRI), Tufts Medical Center. Photo by Dave Fornell

Feature | Tufts Medical Center | August 21, 2020 | Dave Fornell, Editor
The cardiology program at Tufts Medical Center in Boston is internationally recognized for being on the forefront of...
The Medtronic Heartware and Abbott Heartmate 3 LVADs and others currently cleared by the FDA might be easier to use in Medicare advanced heart failure patients under new guidelines proposed by CMS. Photo by Dave Fornell

The Medtronic Heartware and Abbott Heartmate 3 LVADs and others currently cleared by the FDA might be easier to use in Medicare advanced heart failure patients under new guidelines proposed by CMS. Photo by Dave Fornell

Feature | Heart Failure | August 21, 2020 | Dave Fornell, Editor
August 21, 2020 — The U.S. Centers for Medicare and Medicaid Services (CMS) proposed updates to coverage policies for...
Photo of Eyes Predicts Death and Readmission in Heart Failure Patients. Getty Images.

Photo of Eyes Predicts Death and Readmission in Heart Failure Patients. Getty Images.

News | Heart Failure | August 17, 2020
  August 17, 2020 — Pupil size predicts death and hospital readmission in patients with heart failure, according to...
Wearable Sensors and AI App Used to Remotely Monitor Heart Failure Patients in NorthShore Health System. Carnegie Mellon University, Northshore and physIQ launch Study of monitoring technology for high-risk cardiac and surgical patients.
News | Remote Monitoring | August 05, 2020
August 5, 2020 – NorthShore University HealthSystem , Carnegie Mellon University and physIQ are collaborating on a...
Examples of  allogeneic cardiac cells (also called cardiosphere-derived cells or CDCs).

Examples of allogeneic cardiac cells (also called cardiosphere-derived cells or CDCs), that were used to treat heart attack infarcts to reverse heart failure in the ALLSTAR trial.

News | Heart Failure | August 04, 2020
August 4, 2020 - More than three years after a clinical trial was prematurely ended for failing to show progress in...
Two of the top pieces of content in July included the FDA clearance for the new Watchman FLX left atrial appendage occluder (left), which includes a video interview with one of the trial investigators. COVID-19 content remained among the top content in July, and one story explained the odd pattern of cardiac cell death in COVID-19 patient autopsies. 

Two of the top pieces of content in July included the FDA clearance for the new Watchman FLX left atrial appendage occluder (left), which includes a video interview with one of the trial investigators. COVID-19 content remained among the top content in July, and one story explained the odd pattern of cardiac cell death in COVID-19 patient autopsies.

Feature | August 03, 2020 | Dave Fornell, Editor
August 3, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC)...